Literature DB >> 12921315

Phenotype score to grade the severity of thalassemia intermedia.

Shubha R Phadke1, Savita Agarwal.   

Abstract

OBJECTIVE: Thalassemia intermedia is an ill-defined group of thalassemia patients with severity in between thalassemia major and asymptomatic carriers. The severity of cases varies greatly. With availability of information about genetic modifiers of beta-thalassemia phenotype, attempts are being made to study genotype phenotype correlation in thalassemia intermedia.
METHODS: The first important step in genotype, phenotype correlation is well-defined phenotypes. Severity of thalassemia intermedia can not be graded only on haemoglobin level and age of presentation. The authors have developed a phenotype scoring system to subclassify thalassemia intermedia patients into 3 groups, viz, mild, moderate and severe. RESULT: This phenotype scoring system appears to grade the severity correctly depending on various clinical features like age of presentation, severity of anaemia, growth retardation, bone marrow hyperplasia, need of blood transfusions and splenectomy.
CONCLUSION: The classification of thalassemia intermedia will be useful for genotype phenotype correlation, to develop management guidelines for the subgroups and to try new treatment modalities like hydroxyurea, erythropoetin etc.

Entities:  

Mesh:

Year:  2003        PMID: 12921315     DOI: 10.1007/bf02723137

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  6 in total

1.  Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?

Authors:  P J Ho; G W Hall; L Y Luo; D J Weatherall; S L Thein
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

2.  Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype.

Authors:  D Rund; V Oron-Karni; D Filon; A Goldfarb; E Rachmilewitz; A Oppenheim
Journal:  Am J Hematol       Date:  1997-01       Impact factor: 10.047

3.  The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: clinical, haematological, biosynthetic and molecular studies.

Authors:  J Traeger-Synodinos; E Kanavakis; C Vrettou; E Maragoudaki; T Michael; A Metaxotou-Mavromati; C Kattamis
Journal:  Br J Haematol       Date:  1996-12       Impact factor: 6.998

4.  Severe thalassaemia intermedia caused by interaction of homozygosity for alpha-globin gene triplication with heterozygosity for beta zero-thalassaemia.

Authors:  V Oron; D Filon; A Oppenheim; D Rund
Journal:  Br J Haematol       Date:  1994-02       Impact factor: 6.998

5.  Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients.

Authors:  C Camaschella; U Mazza; A Roetto; E Gottardi; A Parziale; M Travi; S Fattore; D Bacchiega; G Fiorelli; M D Cappellini
Journal:  Am J Hematol       Date:  1995-02       Impact factor: 10.047

6.  A novel beta-globin mutation, beta Durham-NC [beta 114 Leu-->Pro], produces a dominant thalassemia-like phenotype.

Authors:  C M de Castro; B Devlin; D E Fleenor; M E Lee; R E Kaufman
Journal:  Blood       Date:  1994-02-15       Impact factor: 22.113

  6 in total
  7 in total

1.  Factors affecting health-related quality of life in Thai children with thalassemia.

Authors:  Montarat Thavorncharoensap; Kitti Torcharus; Issarang Nuchprayoon; Arthorn Riewpaiboon; Kaemthong Indaratna; Bang-On Ubol
Journal:  BMC Blood Disord       Date:  2010-01-21

2.  A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E.

Authors:  Manit Nuinoon; Wattanan Makarasara; Taisei Mushiroda; Iswari Setianingsih; Pustika Amalia Wahidiyat; Orapan Sripichai; Natsuhiko Kumasaka; Atsushi Takahashi; Saovaros Svasti; Thongperm Munkongdee; Surakameth Mahasirimongkol; Chayanon Peerapittayamongkol; Vip Viprakasit; Naoyuki Kamatani; Pranee Winichagoon; Michiaki Kubo; Yusuke Nakamura; Suthat Fucharoen
Journal:  Hum Genet       Date:  2010-03       Impact factor: 4.132

3.  Productivity Loss and Associated Costs Among Patients with Transfusion-Dependent Thalassemia in Dubai, United Arab Emirates.

Authors:  Shaikha Alshamsi; Samer Hamidi; Hacer Ozgen Narci
Journal:  Clinicoecon Outcomes Res       Date:  2021-09-29

4.  Thalassaemia intermedia: an update.

Authors:  Ali T Taher; Khaled M Musallam; Maria D Cappellini
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-08-29       Impact factor: 2.576

5.  Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.

Authors:  Shaikha Alshamsi; Samer Hamidi; Hacer Ozgen Narci
Journal:  BMC Health Serv Res       Date:  2022-03-05       Impact factor: 2.655

Review 6.  Thalassemia Intermedia: Chelator or Not?

Authors:  Yen-Chien Lee; Chi-Tai Yen; Yen-Ling Lee; Rong-Jane Chen
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

Review 7.  When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.

Authors:  A T Taher; A Radwan; V Viprakasit
Journal:  Vox Sang       Date:  2014-10-07       Impact factor: 2.144

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.